News

Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.

BSC and Fresnius Kabi reached a deal facilitated by Evio Pharmacy Solutions by sidestepping pharmacy benefit managers.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

The FDA's decision to issue a CRL was announced on October 08, 2024 and cites issues with the timing of the facility inspection.

This September 2024 month in review highlights recent advances in gene therapies and therapies demonstrating the potential for improved vision outcomes.

HCPLive spoke with Maguire about the benefits of acetylcholine and muscarinic receptors for the treatment of schizophrenia.

This Month in Review article featured a variety of notable updates in the field of pulmonology covered in September 2024.

In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.

In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.

In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.

In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.

Findings highlight HCV infection burden among people without injection drug use, a known risk factor for HCV, and call for universal testing to better capture these individuals.

The biosimilars month in review highlights a new approval and 2023 cost savings

This retrospective analysis examined the current management of early and late anemia in a representative sample of the kidney transplant population in Spain.

These new data provide additional evidence for a range of benzene concentrations detected by in over-the-counter drug products with BPO maintained at room temperature.

A recent study shows the FDA's black-box warnings on antidepressants have led to decreased usage among youth, with an increase in suicide attempts and deaths observed.

This September 2024 month in review spotlights our top coverage of recent nephrology pipeline updates, guidelines, and research.

Anemia is frequently observed in primary care patients with HF and is linked to worse prognosis and comorbidities, including cancer.

The decision by the FDA follows an announcement by Biofrontera that there were no safety issues found following the submission of the medication’s supplemental New Drug Application.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

Test your knowledge of the phase 3 MAESTRO-NASH trial supporting resmetirom (Rezdiffra)’s FDA accelerated approval for MASH with this quiz.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

New data reports a notably heightened risk of atopic dermatitis in patients with prurigo nodulais compared with a control cohort.

In this latest edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news, we highlight updates from across therapeutic pipelines.